Johnson & Johnson

Johnson & Johnson

JNJNYSEHealthcare
$255.56
up +2.28 (+0.90%)

1-Year Price

+37.36% past year
Johnson & Johnson (JNJ) 1-year price chart: up 37.36% from $186.05 on Oct 2025 to $255.56 on Oct 2026. Closing range $185.98 to $278.43.

EquityGlimpse Score

Overall
7.3/10
Wide Moat

Strong, durable competitive advantages versus peers.

Growth
7
Sign up free to see the full breakdown

Valuation, profitability, financial health, dividend and sentiment scores for Johnson & Johnson (JNJ) are available to EquityGlimpse members.

Market Cap
615.87B
P/E Ratio
18.82
EPS
$11.04
52W High
$281.07
52W Low
$184.66
Volume
6.39M
Beta
0.24
Dividend Yield
2.46%
Fair value estimate: sign up to see
Is JNJ over- or undervalued? Run DCF and multiples models on EquityGlimpse.
See fair value

Key Financial Metrics

Price to Sales
5.35
Price to Book
6.18
EV/EBITDA
12.97
Free CF per Share
$8.11
Op. CF per Share
$10.10
Debt to Equity
0.59
Gross Margin
67.88%
Net Margin
28.46%

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

CEO
Joaquin Duato
Industry
Drug Manufacturers - General
Employees
141,700
IPO Date
1962-01-02
Country
US
Website
jnj.com
Unlock Full Analysis

Get the complete picture on Johnson & Johnson

Sign up for EquityGlimpse to access deep fundamental data, AI reports, valuation models, and real-time tracking for JNJ and 8,500+ other stocks.

30 Years of Financials
Income statements, balance sheets, and cash flows with 70+ interactive charts
AI-Powered Analysis
Generate professional research reports with 15+ AI models
DCF Valuation
Run discounted cash flow models with customizable assumptions
Portfolio Tracking
Track real-time P&L, sector allocation, and dividend projections
Earnings Intelligence
Surprise tracking, revision momentum, and whisper estimates
Insider & Congress Trades
Monitor what insiders and Congress members are buying and selling
Start 7-Day Free Trial View Pricing

Starting at $8.25/month. 7-day free trial. Cancel anytime.